Advanced search
Add to list

Development of an androgen receptor (AR) splice variant targeting, cell-free RNA and treatment-predictive biomarker assay for men with metastatic castration-resistant prostate cancer (mCRPC)

Author
Organization

Citation

Please use this url to cite or link to this publication:

MLA
Vanwelkenhuyzen, Jan. “Development of an Androgen Receptor (AR) Splice Variant  Targeting, Cell-Free RNA and Treatment-Predictive Biomarker Assay for Men with Metastatic Castration-Resistant Prostate Cancer (MCRPC).” 9th Belgian Multidisciplinary Meeting on Urological Cancers, Abstracts, 2022.
APA
Vanwelkenhuyzen, J. (2022). Development of an androgen receptor (AR) splice variant  targeting, cell-free RNA and treatment-predictive biomarker assay for men with metastatic castration-resistant prostate cancer (mCRPC). 9th Belgian Multidisciplinary Meeting on Urological Cancers, Abstracts. Presented at the 9th Belgian Multidisciplinary Meeting on Urological Cancers, Brussels, Belgium.
Chicago author-date
Vanwelkenhuyzen, Jan. 2022. “Development of an Androgen Receptor (AR) Splice Variant  Targeting, Cell-Free RNA and Treatment-Predictive Biomarker Assay for Men with Metastatic Castration-Resistant Prostate Cancer (MCRPC).” In 9th Belgian Multidisciplinary Meeting on Urological Cancers, Abstracts.
Chicago author-date (all authors)
Vanwelkenhuyzen, Jan. 2022. “Development of an Androgen Receptor (AR) Splice Variant  Targeting, Cell-Free RNA and Treatment-Predictive Biomarker Assay for Men with Metastatic Castration-Resistant Prostate Cancer (MCRPC).” In 9th Belgian Multidisciplinary Meeting on Urological Cancers, Abstracts.
Vancouver
1.
Vanwelkenhuyzen J. Development of an androgen receptor (AR) splice variant  targeting, cell-free RNA and treatment-predictive biomarker assay for men with metastatic castration-resistant prostate cancer (mCRPC). In: 9th Belgian Multidisciplinary Meeting on Urological Cancers, Abstracts. 2022.
IEEE
[1]
J. Vanwelkenhuyzen, “Development of an androgen receptor (AR) splice variant  targeting, cell-free RNA and treatment-predictive biomarker assay for men with metastatic castration-resistant prostate cancer (mCRPC),” in 9th Belgian Multidisciplinary Meeting on Urological Cancers, Abstracts, Brussels, Belgium, 2022.
@inproceedings{8747829,
  author       = {{Vanwelkenhuyzen, Jan}},
  booktitle    = {{9th Belgian Multidisciplinary Meeting on Urological Cancers, Abstracts}},
  language     = {{eng}},
  location     = {{Brussels, Belgium}},
  title        = {{Development of an androgen receptor (AR) splice variant  targeting, cell-free RNA and treatment-predictive biomarker assay for men with metastatic castration-resistant prostate cancer (mCRPC)}},
  year         = {{2022}},
}